- Home
- LANV vs ABOS Comparison
LANV vs ABOS Comparison
Compare LANV & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$3.42
Company Overview
Basic Information| Metric | LANV | ABOS |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.4M | 155.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LANV | ABOS |
|---|---|---|
| Price | $2.03 | $3.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 48.5K | ★ 289.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.86 |
| 52 Week High | $2.69 | $3.50 |
Technical Indicators
Market Signals| Indicator | LANV | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 60.50 | 67.38 |
| Support Level | $1.91 | $1.21 |
| Resistance Level | $2.27 | N/A |
| Average True Range (ATR) | 0.23 | 0.28 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 57.14 | 78.26 |
Price Performance
Historical Comparison LANV
ABOS
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.